GPT and metabolic dysfunction-associated steatotic liver disease: There is increasing evidence that T2DM subjects have a greater risk of developing NAFLD even in patients with normal Alanine Amino-transaminase (ALT levels).11 To date, there are no Food and Drug Administration (FDA) approved pharmacotherapies available locally for the treatment of NAFLD.